These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 38326175)
41. Use of plant-based hallucinogens and dissociative agents: U.S. Time Trends, 2002-2019. Walsh CA; Livne O; Shmulewitz D; Stohl M; Hasin DS Addict Behav Rep; 2022 Dec; 16():100454. PubMed ID: 36119808 [TBL] [Abstract][Full Text] [Related]
42. Do the therapeutic effects of psilocybin involve actions in the gut? Reed F; Foldi CJ Trends Pharmacol Sci; 2024 Feb; 45(2):107-117. PubMed ID: 38216431 [TBL] [Abstract][Full Text] [Related]
43. Availability of websites offering to sell psilocybin spores and psilocybin. Lott JP; Marlowe DB; Forman RF J Psychoactive Drugs; 2009 Sep; 41(3):305-7. PubMed ID: 19999684 [TBL] [Abstract][Full Text] [Related]
44. DNA-based taxonomic identification of basidiospores in hallucinogenic mushrooms cultivated in "grow-kits" seized by the police: LC-UV quali-quantitative determination of psilocybin and psilocin. Gambaro V; Roda G; Visconti GL; Arnoldi S; Casagni E; Dell'Acqua L; Farè F; Paladino E; Rusconi C; Arioli S; Mora D J Pharm Biomed Anal; 2016 Jun; 125():427-32. PubMed ID: 27021629 [TBL] [Abstract][Full Text] [Related]
45. Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations. Kometer M; Pokorny T; Seifritz E; Volleinweider FX Psychopharmacology (Berl); 2015 Oct; 232(19):3663-76. PubMed ID: 26231498 [TBL] [Abstract][Full Text] [Related]
46. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Griffiths RR; Johnson MW; Carducci MA; Umbricht A; Richards WA; Richards BD; Cosimano MP; Klinedinst MA J Psychopharmacol; 2016 Dec; 30(12):1181-1197. PubMed ID: 27909165 [TBL] [Abstract][Full Text] [Related]
47. Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. Lewis CR; Preller KH; Kraehenmann R; Michels L; Staempfli P; Vollenweider FX Neuroimage; 2017 Oct; 159():70-78. PubMed ID: 28711736 [TBL] [Abstract][Full Text] [Related]
48. The emerging role of psilocybin and MDMA in the treatment of mental illness. Gill H; Gill B; Chen-Li D; El-Halabi S; Rodrigues NB; Cha DS; Lipsitz O; Lee Y; Rosenblat JD; Majeed A; Mansur RB; Nasri F; Ho R; McIntyre RS Expert Rev Neurother; 2020 Dec; 20(12):1263-1273. PubMed ID: 32954860 [TBL] [Abstract][Full Text] [Related]
49. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders. De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683 [TBL] [Abstract][Full Text] [Related]
50. Evaluating the reliability of media reports for gathering information about illegal wildlife trade seizures. Paudel K; Hinsley A; Veríssimo D; Milner-Gulland E PeerJ; 2022; 10():e13156. PubMed ID: 35402091 [TBL] [Abstract][Full Text] [Related]
51. Predictors of Medical Students' Perceptions of Psilocybin-Assisted Therapy for Use in Medical Practice. Wang K; Sun Y; Nava B; Sampiere L; Jacobs RJ Cureus; 2023 Apr; 15(4):e37450. PubMed ID: 37181969 [TBL] [Abstract][Full Text] [Related]
52. Association between law enforcement seizures of illicit drugs and drug overdose deaths involving cocaine and methamphetamine, Ohio, 2014-2019. Zibbell JE; Clarke SD; Kral AH; Richardson NJ; Cauchon D; Aldridge A Drug Alcohol Depend; 2022 Mar; 232():109341. PubMed ID: 35134733 [TBL] [Abstract][Full Text] [Related]
53. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Ross S; Bossis A; Guss J; Agin-Liebes G; Malone T; Cohen B; Mennenga SE; Belser A; Kalliontzi K; Babb J; Su Z; Corby P; Schmidt BL J Psychopharmacol; 2016 Dec; 30(12):1165-1180. PubMed ID: 27909164 [TBL] [Abstract][Full Text] [Related]
54. Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review. Psiuk D; Nowak EM; Dycha N; Łopuszańska U; Kurzepa J; Samardakiewicz M Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232748 [TBL] [Abstract][Full Text] [Related]
56. Supply-side predictors of fatal drug overdose in the Washington/Baltimore HIDTA region: 2016-2020. Lowder EM; Zhou W; Peppard L; Bates R; Carr T Int J Drug Policy; 2022 Dec; 110():103902. PubMed ID: 36343432 [TBL] [Abstract][Full Text] [Related]
57. Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders. Wulff AB; Nichols CD; Thompson SM Neuropharmacology; 2023 Jun; 231():109504. PubMed ID: 36921889 [TBL] [Abstract][Full Text] [Related]
58. Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes. Jones GM; Nock MK J Psychopharmacol; 2022 Jan; 36(1):57-65. PubMed ID: 34983261 [TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. Brown RT; Nicholas CR; Cozzi NV; Gassman MC; Cooper KM; Muller D; Thomas CD; Hetzel SJ; Henriquez KM; Ribaudo AS; Hutson PR Clin Pharmacokinet; 2017 Dec; 56(12):1543-1554. PubMed ID: 28353056 [TBL] [Abstract][Full Text] [Related]
60. Police seizure of drugs without arrest among people who use drugs in Vancouver, Canada, before provincial 'decriminalization' of simple possession: a cohort study. Hayashi K; Singh Kelsall T; Shane C; Cui Z; ; Milloy MJ; DeBeck K; Kerr T Harm Reduct J; 2023 Aug; 20(1):117. PubMed ID: 37644428 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]